genOway
- Company typePrivate
- Founded1999
- HeadquartersLyon, France
- Headcount101–250
- GTM typeB2B
- OfferingServices
genOway firmographics
Firmographics- Name
- genOway
- Legal name
- genOway
- Website
- https://genoway.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
genOway industry classification
Industry- Product category
- Preclinical Research Models
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
- akta.pro secondary industry
- Cloning & Advanced Reproductive Technologies Services (AFAEAJAL)
Keywords
Where genOway is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
genOway business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Off-the-shelf Catalog Models: Sale of pre-validated, ready-to-use genetically modified mouse, rat, and cell line models from extensive catalog. Models include humanized mice, conditional knockouts, immunodeficient rodents, and engineered tumor cell lines.
- Custom Model Generation Services: Bespoke development of genetically modified models tailored to specific scientific requirements. Services include mouse model generation, rat model generation, and cell line generation with scientific expert support throughout the process.
- Strategic Expansion Revenue: Revenue from international subsidiaries including genOway Japan, targeting the third largest preclinical research market globally. Japan subsidiary targets €5-10 million contribution toward €50 million sales goal by 2028 under Route50+DATA strategic plan.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | Off-the-shelf catalog models with certified health status |
| Other | Multi-year contract | Custom model generation services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
genOway product offering
Product offeringCore offering
genOway develops and sells genetically modified preclinical mouse, rat, and cell line models for biopharmaceutical and academic researchers. The company offers both an off-the-shelf catalog of validated humanized models (including humanized FcγR, human immune system, conditional knockouts, immunodeficient strains, and engineered cell lines) and bespoke custom model generation services leveraging proprietary genetic engineering technologies.
Product overview
genOway is a French biotech company specializing in preclinical mouse models and cell lines for predictive drug discovery research. The company offers an integrated portfolio of off-the-shelf genetically modified models and customized model generation services. The core product line includes humanized mouse models (target-specific humanization like genO-hFcγR, genO-hTFRC, genO-hSA/hFcRn, and human immune system models like genO-BRGSF-HIS), T-cell engager models (genO-panhCD3 and its co-stimulatory variants), conditional knockout mice, Cre driver lines, immunodeficient rodents, and engineered cell lines. Customization services enable development of bespoke mouse, rat, and cell line models. Technologies supporting model development include CRISPR/Cas9, RMCE, FLEx, SSR, TET System, Homologous Recombination, SMASh, and IRES. The models support efficacy, safety, pharmacokinetic/biodistribution, and mechanism of action applications across immuno-oncology, neuroscience, and inflammation research areas.
Differentiator
Problem solved
Functional benefit
Products and services
- genO-hFcγR Humanized Fc-gamma receptor mouse model enabling assessment of Fc receptor pathways targeted by therapeutic antibodies for translational efficacy and safety evaluation in drug discovery.
- genO-hFcγR/hFcRn Double-humanized mouse model combining Fc-gamma receptor and FcRn humanization to improve both PK assessment and effector function evaluation of compounds with extended half-life through FcRn binders.
- genO-hFcγR/hIgG1 Double-humanized mouse model expressing humanized FcγR and human IgG1 to improve tolerability assessment of human IgG1 therapeutic antibodies.
- genO-hSA/hFcRn (AlbuMus) Double-humanized mouse model for preclinical development of human serum albumin and FcRn-oriented therapeutics, enabling PK/PD studies and half-life assessment of biologics.
- genO-hTFRC Fully immunocompetent humanized mouse model for in vivo efficacy assessment of compounds targeting human transferrin receptor (TFRC/CD71) for drug delivery across the blood-brain barrier.
- genO-hTFRC/hFcγR Double-humanized mouse model combining TFRC and FcγR humanization for improved biodistribution assessment and drug shuttling through the blood-brain barrier with functional Fc effector capability.
- genO-hTFRC/hSA/hFcRn Triple-humanized mouse model combining TFRC, serum albumin, and FcRn humanization for PK assessment of drugs crossing the blood-brain barrier with extended half-life optimization.
- genO-BRGSF-HIS Human immune system mouse model reconstituted with human CD34+ hematopoietic stem cells, generating functional lymphoid and myeloid compartments for translational CRS modeling and complex immune interaction studies.
- genO-panhCD3 Immunocompetent mouse model with humanized CD3 complex (ε, γ, δ chains) enabling efficacy and safety assessment of T-cell engagers with endogenous T cell development and native CD3/TCR signaling.
- genO-panhCD3/hCD28 Double-humanized immunocompetent mouse model enabling evaluation of anti-CD3 and CD28 compounds for T-cell engager development with coordinated signal 1 and signal 2 assessment.
- genO-panhCD3/hCD137 Double-humanized immunocompetent mouse model expressing human CD3 and CD137 (4-1BB) for evaluation of next-generation T-cell engagers incorporating co-stimulatory signals.
- Custom Mouse Model Generation Service Bespoke mouse model generation service drawing on 25 years of experience in genetically modified model design, tailored to specific research needs with scientific expert support throughout the project.
- Custom Rat Model Generation Service Predictive rat model generation service bringing research closer to human physiology through bespoke genetically modified rat models for research programs.
- Custom Cell Line Generation Service Predictive cell model generation service to elevate precision and efficiency of research through tailored cell line engineering.
Quantifiable outcome
- genO-hFcγR model enables more accurate prediction of therapeutic antibody efficacy and safety in humans by addressing species-specific Fcγ receptor differences
- +2 more outcomes
Companies that use genOway
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles4 records
genOway technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
genOway partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- genOway JapancoreFirst wholly-owned subsidiary established in Japan, the third largest preclinical research market globally. Appointed Dr. Hideki Hanaoka as representative director and Mr. Philippe Foucher as chairman of the board. Part of Route50+DATA strategic plan targeting €50 million in sales by 2028, with Japan expected to contribute €5-10 million. Target of building a five-scientist team within a year.
- argenxcoreInternational consortium co-development of genO-hFcγR mouse model for more accurate prediction of therapeutic antibody efficacy and safety in humans. Study published in Science Immunology demonstrated model enables ranking of antibody candidates and measurement of immune cell targeting.
- Innate PharmacoreCo-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation of humanized FcγR model for antibody therapy prediction.
- Vir BiotechnologycoreCo-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation demonstrating accurate prediction of therapeutic antibody efficacy and safety.
- VIB-Ghent UniversitycoreScientific coordination of international consortium for genO-hFcγR mouse model development. Study published in Science Immunology.
- Taconic BiosciencescoreBreeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from AAALAC-accredited facilities.
- Charles River LaboratoriescoreBreeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from PHS-assured professional breeders.
- Crown BioscienceminorScientific collaboration on HSA/hFcRn models. Published scientific articles and posters on ADC pharmacokinetic prediction using genO-hSA/hFcRn mice.
- EvotecminorCollaboration on humanized immune system mice for therapeutic antibody development. Presented at SITC 2025 on mice humanized for the immune system as validated tool for therapeutic antibody development.
- LundbeckminorValidated genO-hTFRC model for drug delivery to the brain. Presented anti-TFRC/anti-BACE1 antibody data demonstrating efficient shuttling of therapeutic antibodies to the brain at AACR 2024.
- GSKminorCollaboration partner for HSA/FcRn models in drug development. Scientific publication on in vivo half-life extension of BMP1/TLL metalloproteinase inhibitors using small-molecule human serum albumin binders.
- AvactaminorPK and biodistribution studies of Affimer biotherapeutics targeting PD-L1 using HSA/FcRn models. Poster presented at AACR 2021.
- Crescendo BiologicsminorCB307 bispecific costimulatory Humabody development using HSA/FcRn models for half-life extension. Clinical Cancer Research publication and AACR 2024 poster.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
genOway competitors and assessment
Company assessmentRegional players
- Janvier Labs: Janvier Labs is a French/European rodent model provider focused on laboratory animal production. It competes with genOway in the European market for standard and genetically defined rodent models, though with a less specialized humanized model portfolio.
Broad incumbents
- WuXi AppTec: WuXi AppTec is a large global CRO/CDMO with preclinical model and biologics development services. It competes for the same biopharma R&D wallet as genOway, particularly for biotech customers seeking integrated preclinical packages with rodent models.
- Crown Bioscience: Crown Bioscience is a global preclinical CRO offering oncology and immuno-oncology services, and a research collaborator with genOway on HSA/hFcRn models. Competes at the contract research layer where genOway's model customers also procure CRO services.
- Charles River Laboratories: Charles River is a major preclinical CRO and rodent model distributor that both partners with genOway (for breeding/distribution) and competes through its own Research Models & Services segment, including humanized mouse lines via Crystal Bioscience.
Emerging players
- Inotiv: Inotiv (formed via Envigo acquisition) provides preclinical research models and services including genetically engineered rodent models. Competes with genOway in research models and contract research services for biopharma, with broader but less specialized offerings.
- Cyagen Biosciences: Cyagen is an emerging custom rodent model generation provider, particularly strong in Asia, offering CRISPR-based knockout/knockin and humanized mouse services. Competes with genOway's customized model generation offering, especially for biotech customers seeking cost-competitive bespoke models.
- TransCure bioServices: TransCure bioServices offers humanized mouse models and preclinical services for immuno-oncology, infectious disease, and inflammation research. Overlaps with genOway's HIS-mouse and FcγR-humanized franchises for early-stage biotech customers.
Direct peers
- The Jackson Laboratory: JAX is the leading nonprofit provider of genetically defined mouse models for biomedical research. It directly competes with genOway in conditional knockouts, Cre driver lines, immunodeficient models, and humanized mice supplied to pharma and academia worldwide.
- Taconic Biosciences: Taconic is a direct peer and simultaneous distribution partner of genOway, providing genetically engineered rodent models and breeding services to pharma/biotech. Both compete in humanized and disease-model mouse lines while also collaborating on fulfillment for genOway's catalog.
- Crystal Bioscience (Charles River): Crystal Bioscience (now part of Charles River) develops humanized mouse models for immuno-oncology and antibody therapeutic research. Directly comparable to genOway's humanized FcγR and immune system models for therapeutic antibody development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
genOway social profiles
Digital presencegenOway financial estimates
Financial estimateRevenue estimate
Valuation estimate
genOway leadership team
Management profileNumber of profiles
Profiles3 records
genOway subsidiaries and ownership
Company hierarchySubsidiaries1 record
genOway funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
genOway M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about genOway
What does genOway do?
genOway develops and sells genetically modified preclinical mouse, rat, and cell line models for biopharmaceutical and academic researchers. The company offers both an off-the-shelf catalog of validated humanized models (including humanized FcγR, human immune system, conditional knockouts, immunodeficient strains, and engineered cell lines) and bespoke custom model generation services leveraging proprietary genetic engineering technologies.
Is genOway a public or private company?
genOway is a private company. It is classified as public and is currently operating.
When was genOway founded?
genOway was founded in 1999. It employs 101 to 250 people.
Where is genOway based?
genOway is headquartered in Lyon, France, in the Europe region.
How does genOway make money?
Three revenue lines are on record. Off-the-shelf Catalog Models are the primary driver. The others are custom Model Generation Services and strategic Expansion Revenue.
Who are genOway's main competitors?
Janvier Labs is listed as a regional player. Broad incumbents are WuXi AppTec, Crown Bioscience and Charles River Laboratories. Emerging players are Inotiv, Cyagen Biosciences and TransCure bioServices. Direct peers are The Jackson Laboratory, Taconic Biosciences and Crystal Bioscience (Charles River).
Does genOway have an API?
No public API is recorded for genOway.
What industry is genOway in?
genOway's product category is Preclinical Research Models. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of AFAEAJAL, Cloning & Advanced Reproductive Technologies Services. Its NAICS code is 541714 and its SIC code is 8731.